



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/</u> <u>Verified</u>
LGII1 Ab IgG Screen by IFA, Serum	Detected		[<1:10]	19-259-900232	16-Sep-19 20:45:00	16-Sep-19 20:45:00	17-Sep-19 18:40:30
LGII1 Ab IgG Titer by IFA, Serum	1:1280 *		[<1:10]	19-259-900232	16-Sep-19 20:45:00	16-Sep-19 20:45:00	17-Sep-19 18:40:35

16-Sep-19 20:45:00 LGII1 Ab IgG Screen by IFA, Serum
 LGII1 Antibody, IgG is detected. Titer results to follow.

16-Sep-19 20:45:00 LGII1 Ab IgG Screen by IFA, Serum:
 INTERPRETIVE INFORMATION: LGII1 Ab IgG w/Reflex to Titer,
 Serum
 Leucine-rich, glioma-inactivated 1 protein (LGII1) IgG antibody may occur as part of the
 voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGII1 IgG antibody is mainly associated with limbic encephalitis,
 hyponatremia and myoclonic movements. LGII1 IgG antibody is rarely associated with tumors
 but may occur infrequently in Morvan syndrome, neuromyotonia and idiopathic epilepsy. The
 full-spectrum of clinical disorders associated with the LGII1 IgG antibody continues to be
 defined. Results should be interpreted in correlation with the patient's clinical history
 and other laboratory findings.

This indirect fluorescent antibody assay utilizes leucine-rich, glioma-inactivated 1
 protein (LGII1) transfected cell lines for the detection and semi-quantification of the
 LGII1 IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance
 Statement D: aruplab.com/CS

16-Sep-19 20:45:00 LGII1 Ab IgG Titer by IFA, Serum:
 INTERPRETIVE INFORMATION: LGII1 Ab Titer IgG by IFA,
 Serum

Test developed and characteristics determined by ARUP Laboratories. See Compliance
 Statement D: aruplab.com/CS

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab